Intervention not reported
Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
MST vs ECT ‐ adverse events that led to discontinuation of treatment (short term) · patients with schizophrenia
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes withdrawls or drug discontinuation due to adverse events during 24… compared with placebo? (very low certainty).
1 finding from 1 review
OR 2.43 [0.91, 6.49]
Studies not reported
Very low
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
1 finding from 1 review
Retention [ · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).
1 finding from 1 review